Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia
NCT00490516Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jun 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norclozapine in schizophrenia (3 arms), sponsored by Acadia Pharmaceuticals. Primary endpoint: Positive and Negative Syndrome Scale at 6 weeks. Started Jun 2007; status: completed.
02
Drugs
norclozapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00490516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490516.